PA
DRUG

Perceptive Advisors’s Bright Minds Biosciences DRUG Stock Holding History

Perceptive Advisors’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$27.5M Sell
377,544
-71,746
-16% -$5.78M 0.54% 41
2025
Q4 		$35.1M Hold
449,290
– – 0.63% 44
2025
Q3 		$27.3M Buy
449,290
+28,600
+7% +$1.11M 0.79% 37
2025
Q2 		$11M Sell
420,690
-23,959
-5% -$718K 0.41% 50
2025
Q1 		$16M Buy
444,649
+41,000
+10% +$1.5M 0.57% 40
2024
Q4 		$14.5M Buy
+403,649
New +$14.2M 0.4% 49

Other funds holding DRUG

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Perceptive Advisors's DRUG Position: Q1 2026 in Review

Perceptive Advisors reduced its Bright Minds Biosciences (DRUG) stake by 16% in Q1 2026, selling an estimated $5.78M and leaving 377,544 shares worth $27.5M. The position accounts for 0.54% of the portfolio, ranked #41.

Perceptive Advisors first reported a position in DRUG in Q4 2024 and has held it in 6 quarters since. The position peaked at $35.1M in Q4 2025. 94 funds tracked by Wall St. Rank hold DRUG as of Q1 2026.

  • Perceptive Advisors held 377,544 shares of Bright Minds Biosciences worth $27.5M as of Q1 2026.
  • Perceptive Advisors sold 71,746 Bright Minds Biosciences shares in Q1 2026, an estimated $5.78M.
  • Bright Minds Biosciences made up 0.54% of Perceptive Advisors's portfolio in Q1 2026, its #41 holding.
  • Perceptive Advisors first reported a position in Bright Minds Biosciences in Q4 2024 and has held it in 6 quarters since.
  • Perceptive Advisors's Bright Minds Biosciences position peaked at $35.1M in Q4 2025.
  • 94 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q1 2026.

Based on Perceptive Advisors's 13F filing for Q1 2026, filed 15 May 2026.